New Collaboration Compound Supplement to the Collaboration Agreement by and between EPIRUS SWITZERLAND GmbH and LIVZON MABPHARM INC.EPIRUS Biopharmaceuticals, Inc. • November 16th, 2015 • Pharmaceutical preparations
This New Collaboration Compound Supplement (this “Supplement”), dated as of September 24th , 2015 (the “Supplement Effective Date”), to the Collaboration Agreement (as defined below), by and between EPIRUS SWITZERLAND GmbH, a Swiss corporation, having its principal place of business at General Guisan-Strasse 6, 6303, Zug, Switzerland (“Epirus”), and LIVZON MABPHARM INC., a company organized and existed under the laws of China with legal address at No. 38 Chuangye North Road, Jinwan, Zhuhai, Guangdong, China 519090 (“Livzon”). Epirus and Livzon are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENT BY AND BETWEEN EPIRUS SWITZERLAND GMBHCollaboration Agreement • November 16th, 2015 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
This Collaboration Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of July 13, 2015 (the “Effective Date”), by and between Epirus Switzerland GmbH, a Swiss corporation, having its principal place of business at General-Guisan-Strasse 6, 6303, Zug, Switzerland (“Epirus”), and Swiss Pharma International AG, a Swiss corporation, with an address at Waldmannstrasse 8, 8001, Zurich, Switzerland (“Partner”). Epirus and Partner are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
